Stock listing

Munich:AJ8 Agenus Inc. Aktie

German listing (Munich) of Agenus Inc. · home listing NASDAQ:AGEN

Follow Agenus Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:AGEN

$5.97 USD -0.43 (-6.7%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:AGEN

Past year +39.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$5.90 – $6.26 USDNov 20, 2026
Volume
711,696 sharesNov 20, 2026
Market cap
$270.1M USDAt the close on Nov 20, 2026 · price × 45.25M shares outstanding
52-week range
$2.71 – $10.31 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$7.02M USDMedian day 782,800 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Agenus Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:AGEN · Home$5.97 USD-0.43 (-6.7%)711,696$6.00$6.26$5.90$6.40Close on Nov 20, 2026
Frankfurt:AJ8€5.40 EUR-0.35 (-6.1%)—€5.45€5.45€5.40€5.75Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:AGEN · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$5.97-0.43-6.7%$6.00$6.26$5.90711,696
$6.40+0.19+3.1%$6.17$6.50$5.98880,001
$6.21-0.08-1.3%$6.19$6.447$5.96856,952
$6.29-0.44-6.5%$6.60$6.665$6.245568,264
$6.73-0.14-2.0%$6.97$6.97$6.50464,089
$6.87-0.35-4.8%$7.07$7.085$6.775498,928
$7.22+0.20+2.8%$7.13$7.29$7.02429,708
$7.02-0.13-1.8%$7.09$7.13$6.645691,626
$7.150.000.0%$7.39$7.65$7.111840,731
$7.15+0.71+11.0%$6.54$7.20$6.372862,177
$6.44-0.53-7.6%$6.81$6.82$6.111,330,816
$6.97+0.30+4.5%$6.99$7.06$6.85729,893
$6.67+0.14+2.1%$6.59$6.835$6.50499,019
$6.53-0.31-4.5%$6.85$6.855$6.43595,081
$6.84-0.25-3.5%$6.91$7.09$6.69564,302
$7.09-0.04-0.6%$7.13$7.30$6.942624,978
$7.13+0.48+7.2%$6.51$7.14$6.47744,010
$6.65+0.49+8.0%$6.13$6.67$6.11838,971
$6.16-0.17-2.7%$6.49$6.49$6.14687,566
$6.33-0.18-2.8%$6.50$6.50$6.16509,035
$6.51+0.11+1.7%$6.32$6.52$6.236553,901
$6.40-0.02-0.3%$6.459$6.54$6.31789,524
$6.42+0.24+3.9%$6.10$6.58$6.05819,337
$6.18+0.14+2.3%$6.13$6.30$6.055734,858
$6.04-0.64-9.6%$6.65$6.70$6.001,028,732
$6.68+0.18+2.8%$6.52$6.99$6.51815,431
$6.50-0.45-6.5%$6.88$7.14$6.46980,140
$6.95-0.48-6.5%$7.30$7.34$6.81991,800
$7.43-0.24-3.1%$7.63$7.66$7.39572,500
$7.67+0.13+1.7%$7.50$7.79$7.38710,200
$7.54-0.03-0.4%$7.57$7.66$7.241,214,800
$7.57+0.08+1.1%$7.28$7.62$7.271,155,100
$7.49-1.24-14.2%$8.49$8.49$7.471,522,900
$8.73+0.37+4.4%$8.54$8.76$8.11956,100
$8.36+0.03+0.4%$8.36$8.61$8.081,085,200
$8.33-1.60-16.1%$9.95$9.99$8.281,949,200
$9.93+0.04+0.4%$9.92$10.31$9.621,366,600
$9.89+0.46+4.9%$9.66$10.06$9.431,500,000
$9.43+0.89+10.4%$8.71$9.71$8.472,764,000
$8.54+0.04+0.5%$8.57$8.68$8.40672,400
$8.50+0.10+1.2%$8.32$8.60$8.20635,700
$8.40-0.30-3.4%$8.70$8.70$8.39610,000
$8.70+0.37+4.4%$8.26$8.82$8.16993,300
$8.33+0.48+6.1%$7.80$8.60$7.601,299,400
$7.85+0.63+8.7%$7.48$7.88$7.332,084,000
$7.22+0.01+0.1%$7.31$7.40$7.09765,400
$7.21+0.05+0.7%$7.25$7.33$7.06686,000
$7.16+0.03+0.4%$7.05$7.19$6.81779,500
$7.13+0.19+2.7%$7.03$7.18$6.82752,200
$6.94+0.05+0.7%$6.93$7.02$6.70790,500
$6.89+0.03+0.4%$6.76$7.04$6.66893,600
$6.86-0.57-7.7%$7.60$7.61$6.781,445,700
$7.43-0.81-9.8%$8.14$8.18$7.421,207,300
$8.240.000.0%$8.14$8.38$7.99986,200
$8.24+0.15+1.9%$8.12$8.31$7.98738,700
$8.09+0.10+1.3%$8.07$8.28$7.69663,700
$7.99+0.38+5.0%$7.56$8.00$7.54676,300
$7.61-0.05-0.7%$7.68$7.76$7.50719,300
$7.66-0.15-1.9%$7.98$8.07$7.61741,100
$7.81-0.44-5.3%$8.28$8.52$7.78782,800
$8.25-0.11-1.3%$8.30$8.40$8.03776,700
$8.36+0.69+9.0%$7.80$8.50$7.801,181,200
$7.67-0.42-5.2%$8.07$8.07$7.60772,900
$8.09+0.60+8.0%$7.58$8.35$7.581,517,300
$7.49-0.77-9.3%$8.22$8.25$7.311,575,700

Splits

2 splits since 2011 · NASDAQ:AGEN · every price before a split is adjusted for it

DayRatioWhat
1-for-20Consolidation
1-for-6Consolidation
Ticker
Munich:AJ8
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Munich
Currency
EUR

What changed lately

Latest news

All Agenus Inc. news

Agenus Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
43 in the last 12 months · 184 in all · newest Nov 6, 2026 · oldest 2019
Calls
19 calls with a replay · 19 with a transcript · latest Aug 27, 2025
Decks
34 decks · latest November 2026

Where Agenus Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:AGEN · Home listingNASDAQUnited StatesUSD
LS Exchange:A403RKLS ExchangeGermanyEUR
Lang & Schwarz:A403RKLang & SchwarzGermanyEUR
gettex:AJ8gettexGermanyEUR
BX Swiss:AGENBX SwissSwitzerlandCHF
BOATS:AGENBOATSUnited StatesUSD
Dusseldorf:AJ8DusseldorfGermanyEUR
Frankfurt:AJ8FrankfurtGermanyEUR
Munich:AJ8 · This pageMunichGermanyEUR
Tradegate:AJ8TradegateGermanyEUR

Valuation

EV/sales 1.6× against a median of 252×: the lowest of 3 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$218.3M USD
P/E
9.2×
EV/sales
1.6×
EV/EBITDA
4.0×
Price/book
Negative equity
Gross margin
100.0%
Operating margin
38.9%
Net margin
22.0%
Debt to equity
Negative equity
Beta vs S&P 500
1.80

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Agenus Inc. · NASDAQ:AGENUS$270.1MUS$218.3M9.2×1.6×4.0×n/a22.0%n/a1.80
Fulcrum Therapeutics, Inc. · NASDAQ:FULCUS$281.8M−US$17.87Mn/an/an/a0.9×n/a0.0×0.42
Circio Holding ASA · OSL:CRNAUS$281.1MUS$225.9Mn/an/an/a5.3×n/a0.0×n/a
Relmada Therapeutics, Inc. · NASDAQ:RLMDUS$279.5MUS$77.42Mn/an/an/a1.4×n/a0.0×1.57
Benitec Biopharma Inc. · NASDAQ:BNTCUS$276.1MUS$99.78Mn/an/an/a1.6×n/a0.0×1.46
Vicore Pharma Holding AB · OMXSTO:VICOUS$271.4MUS$182.7Mn/a467×n/a3.3×n/a0.0×n/a
Galectin Therapeutics Inc. · NASDAQ:GALTUS$271.4MUS$293.0Mn/an/an/an/an/an/a1.20
AgomAb Therapeutics NV · NASDAQ:AGMBUS$268.4M−US$6.88Mn/an/an/a0.9×n/a0.0×1.29
Kyverna Therapeutics, Inc. · NASDAQ:KYTXUS$263.5MUS$117.8Mn/an/an/a2.0×n/a0.2×2.02
PepGen Inc. · NASDAQ:PEPGUS$261.8MUS$172.6Mn/an/an/a2.5×n/a0.1×1.11
Ocugen, Inc. · NASDAQ:OCGNUS$260.6MUS$178.1Mn/a37.3×n/an/an/an/a1.47
Median of the othersUS$271.4MUS$145.2M252×1.8×0.0×1.38

Forecasts

3 strong buy · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.

Price target
27.00 USD · Analysts' mean
EPS, year to Dec 2026
0.82 · 1 analyst
Revenue, year to Dec 2026
130.7M · 2 analysts

Team and board

Officers

OfficerRole
Garo H. ArmenChairman and Chief Executive Officer
Jennifer BuellPresident and CEO of MiNK Therapeutics and Chairman, Executive Council at Agenus
Brian CorvesePresident and founder of Vencor Capital
Zack ArmenVP, Corporate Development & Investor Relations
Craig WinterChief Information Officer
José IglesiasChief Medical Affairs Officer
Robin TaylorChief Commercial Officer
Steven O’DayChief Medical Officer
Susan HirschManaging Director at Nuveen
Tracy Mazza ClementeChief People Officer

Board

DirectorRole
Garo H. ArmenChairman and Chief Executive Officer
Jennifer BuellPresident and CEO of MiNK Therapeutics and Chairman, Executive Council at Agenus
Timothy R. WrightLead Director
Tom HarrisonDirector

Events

Calls

CallWhenStatus
Agenus (NASDAQ:AGEN) Q2 2025 Earnings CallWed, Aug 27, 2025 · 9:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q4 2024 Earnings CallTue, Mar 11, 2025 · 8:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q3 2024 Earnings CallTue, Nov 12, 2024 · 8:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q1 2024 Earnings CallTue, May 07, 2024 · 9:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q4 2023 Earnings CallThu, Mar 14, 2024 · 8:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q3 2023 Earnings CallTue, Nov 07, 2023 · 9:00 AM ETReplay
Agenus (NASDAQ:AGEN) Q1 2023 Earnings CallTue, May 09, 2023 · 8:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q4 2022 Earnings CallTue, Mar 14, 2023 · 8:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q3 2022 Earnings CallTue, Nov 08, 2022 · 8:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q2 2022 Earnings CallTue, Aug 09, 2022 · 8:30 AM ETReplay
All 19 calls
CallWhenStatus
Agenus (NASDAQ:AGEN) Q1 2022 Earnings CallTue, May 10, 2022 · 8:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q4 2021 Earnings CallTue, Mar 01, 2022 · 8:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q3 2021 Earnings CallTue, Nov 09, 2021 · 8:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q2 2021 Earnings CallMon, Aug 09, 2021 · 8:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q1 2021 Earnings CallThu, May 06, 2021 · 8:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q4 2020 Earnings CallMon, Mar 15, 2021 · 8:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q3 2020 Earnings CallThu, Oct 29, 2020 · 8:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q2 2020 Earnings CallThu, Aug 06, 2020 · 8:30 AM ETReplay
Agenus (NASDAQ:AGEN) Q1 2020 Earnings CallThu, May 07, 2020 · 8:30 AM ETReplay

Results days

QuarterResultsShare move
Q3 2026Nov 5, 2026 · After close+11.0%
Q2 2026Aug 7, 2026−6.5%
Q1 2026May 11, 2026 · After close+5.5%
Q4 2025Mar 16, 2026+28.7%
Q3 2025Nov 10, 2025 · After close+1.4%
Q2 2025Aug 11, 2025 · After close+12.7%
Q1 2025May 12, 2025 · After close−3.4%
Q4 2024Mar 12, 2025 · Before open−9.0%
Q3 2024Nov 12, 2024 · Before open−20.4%
Q2 2024Aug 8, 2024 · Before open+3.9%
All 20 quarters
QuarterResultsShare move
Q1 2024May 7, 2024 · Before open−7.3%
Q4 2023Mar 14, 2024 · Before open−8.9%
Q3 2023Nov 7, 2023 · Before open+4.9%
Q2 2023Aug 8, 2023 · Before open−8.1%
Q1 2023May 9, 2023 · Before open−5.7%
Q4 2022Mar 14, 2023 · Before open+4.7%
Q3 2022Nov 8, 2022 · Before open−6.7%
Q2 2022Aug 9, 2022 · Before open−1.9%
Q1 2022May 10, 2022 · Before open+9.2%
Q4 2021Mar 1, 2022 · Before open−4.1%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (November 2026)Investor deck33 slidesNovember 2026
Investor Presentation (October 2026)Investor deck33 slidesOctober 2026
Corporate Update (July 2026)Corporate update31 slidesJul 13, 2026
Investor Presentation (April 2026)Investor deck24 slidesApril 2026
Agenus Corporate Event at ESMO 2023Conference34 slidesOct 22, 2023
Technical Presentation (June 2023)Technical17 slidesJune 2023
2023 ASCO Gastrointestinal Cancers SymposiumConference10 slidesJan 21, 2023
2023 ASCO Gastrointestinal Cancers SymposiumConference10 slidesJan 21, 2023
Technical Presentation (November 2022)Technical18 slidesNov 15, 2022
SITC 37th Annual Meeting 2022Conference18 slidesNov 12, 2022
All 34 decks
DeckKindSlidesDate
Investor Day (November 2022)Investor day131 slidesNov 12, 2022
ESMO World Congress on Gastrointestinal Cancer 2022Conference22 slidesJul 2, 2022
Corporate Update (May 2021)Corporate update6 slidesMay 18, 2021
William Blair Webcast on AGEN1181 and Balstilimab AACR Presentations (April 2021)Conference5 slidesApr 10, 2021
Q2 2020 Earnings PresentationEarnings23 slidesAugust 2020
Q1 2020 Earnings PresentationEarnings18 slidesMay 7, 2020
FY2019 Earnings PresentationEarnings7 slidesMar 12, 2020
Investor Day (February 2020)Investor day87 slidesFeb 20, 2020
Investor Day (November 2019)Investor day127 slidesNov 15, 2019
Q3 2019 Earnings PresentationEarnings9 slidesNov 4, 2019
2019 Cantor Fitzgerald Global Healthcare ConferenceConference23 slidesOct 4, 2019
2018 Jefferies London Healthcare ConferenceConference29 slidesNov 14, 2018
Jefferies 2018 Healthcare ConferenceConference22 slidesJun 7, 2018
Deutsche Bank's 43rd Annual Health Care Conference (May 2018)Conference26 slidesMay 8, 2018
Jefferies IO Cell Therapy Summit 2018Conference16 slidesApr 3, 2018
Jefferies 2017 London Healthcare ConferenceConference30 slidesNov 15, 2017
Ladenburg Thalmann 2017 Healthcare ConferenceConference30 slidesSep 26, 2017
Investor Presentation (June 2017)Investor deck21 slidesJun 6, 2017
Investor Presentation (August 2016)Investor deck19 slidesAugust 2016
Jefferies 2016 Healthcare ConferenceConference29 slidesJune 2016
Investor Day (November 2015)Investor day114 slidesNov 19, 2015
Investor Day (May 2015)Investor day93 slidesMay 14, 2015
Investor Presentation (February 2014)Investor deck33 slidesFeb 4, 2014
Investor Presentation (March 2011)Investor deck20 slidesMar 9, 2011

Open Decks

Financings

RaiseDate
Private placement of common stock or pre-funded warrants with Series A and Series B purchase warrants
Announced: US$85M–US$340M · an accompanying Series A purchase warrant and Series B purchase warrant that, if fully…
Buyers: Commodore Capital; RA Capital Management; TCGX; Invus; Ligand Pharmaceuticals
Use of proceeds: Advance BOT+BAL in neoadjuvant MSS colon cancer, including the registrational Phase 3 ROBBIN trial
Jul 13, 2026
Strategic investment of common stock
Closed: US$16M raised · US$7.5 a share · Porrima Ltd +1
Dealers: Porrima Ltd, Biotech Value Advisors (BVA)
Buyers: Zydus ($16 million of Agenus common stock (~2.1 million shares at $7.50 per share))
Jan 15, 2026
Strategic investment of common stock
Announced: about US$16M · US$7.5 a share
Buyers: Zydus (approximately 2.1 million shares of common stock at $7.50 per share, approximately $16 million)
Use of proceeds: Working capital and general corporate purposes, and to accelerate clinical development, registration and potential commercialization of BOT/BAL
Jun 3, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue114.2M103.5M156.3M98.0M295.7M88.2M150.0M36.8M42.9M22.6M
Cost of revenue1.02M486.0K3.11M10.6M3.47M2.35M168.3M124.6M116.1M95.0M
Gross profit33.8M-52.6M-81.4M-99.2M113.6M-56.8M-18.3M-87.8M-73.2M-72.4M
Research and development79.3M155.5M234.6M186.7M178.6M142.6M168.3M124.6M116.1M95.0M
Selling, general and administrative54.4M71.9M78.7M81.0M76.4M59.2M46.0M37.3M33.7M33.1M
Operating income-20.2M-120.5M-159.5M-179.4M25.7M-117.2M-70.1M-123.8M-103.8M-107.5M
Depreciation and amortization10.00M13.3M13.6M6.95M6.79M7.18M6.66M6.29M6.01M4.95M
EBITDA-10.2M-107.1M-146.0M-172.5M32.5M-110.1M-63.5M-117.5M-97.8M-102.5M
Interest expense55.6M120.4M103.9M64.1M65.7M61.1M41.5M25.3M31.3M19.4M
Income before tax-3.08M-232.3M-257.4M-230.7M-28.7M-182.9M-111.6M-162.0M-120.7M-127.0M
Income tax0000000000
Net income-101.0K-227.4M-246.0M-220.3M-24.1M-181.1M-107.9M-159.9M-120.7M-127.0M
Earnings per share, basic0.00-10.59-13.75-15.64-0.11-1.05-0.80-1.44-1.23-1.46
Earnings per share, diluted0.00-10.59-13.75-15.64-0.11-1.05-0.80-1.44-1.23-1.46

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents3.00M40.4M76.1M178.7M291.9M99.9M61.8M53.1M60.2M71.4M
Short-term investments0447.0K14.7M15.0M0004.99M
Receivables1.83M407.0K25.8M2.74M1.52M1.16M16.3M938.0K1.13M11.4M
Inventory113.8M20.4M10.7M055.0K79.5K88.2K
Current assets133.4M45.6M112.4M213.1M332.0M113.8M86.5M74.8M73.6M91.3M
Property, plant and equipment15.5M120.1M133.4M133.0M60.0M26.8M26.3M25.1M26.2M25.6M
Goodwill24.1M24.1M24.7M25.5M24.9M25.5M23.2M22.9M23.0M22.4M
Total assets226.8M226.3M313.9M413.6M466.0M214.5M155.3M136.4M138.4M157.0M
Accounts payable83.0M61.5M61.4M40.9M30.5M17.0M13.6M13.6M8.09M5.43M
Current liabilities323.5M221.4M255.9M189.0M156.9M129.9M122.2M68.1M56.4M40.9M
Long-term debt030.5M12.8M12.6M12.8M18.9M13.4M13.2M142.4M130.5M
Total debt89.3M33.2M12.9M13.2M13.6M19.7M14.0M13.4M163.0M130.7M
Total liabilities504.7M532.7M462.3M468.5M418.0M426.0M386.7M310.9M214.2M196.1M
Shareholders' equity-271.1M-326.4M-160.3M-61.3M34.4M-203.7M-225.4M-172.5M-75.8M-39.1M
Shares outstanding35.3M23.6M19.7M25.3M418.9M332.5M257.2M204.7M161.6M134.2M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-77.2M-158.3M-224.2M-175.4M10.1M-139.1M-18.7M-131.1M-94.2M-80.0M
Capital spending-6.00K-576.0K-9.95M-53.1M-33.8M-3.47M-4.66M-3.60M-3.12M-12.5M
Free cash flow-77.2M-158.9M-234.2M-228.4M-23.7M-142.6M-23.3M-134.7M-97.3M-92.5M
Cash from investing1.19M27.0K3.40M-33.6M-43.1M-4.44M-4.66M-3.59M2.06M17.6M
Cash from financing36.6M122.8M119.9M95.8M225.3M183.9M31.3M128.3M80.5M-2.46M
Dividends paid-9.13M0-16.0M-1.18M
Share buybacks-87.0K0-5.17M-3.79M-1.65M176.4M30.0M86.0M-527.0K-667.0K
Change in cash-39.4M-35.7M-101.6M-113.3M192.1M40.7M8.75M-7.13M-11.3M-65.3M

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G · Big-stake noticeNov 16, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeNov 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportNov 5, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026ResultsSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipOct 2, 2026Insider tradeSEC
4 · Change in ownershipSep 16, 2026Insider tradeSEC
3 · Initial statement of ownershipSep 15, 2026Insider tradeSEC
S-3 · Registration statementSep 11, 2026Offer documentSEC
S-8 · Registration statement for employee plansSep 2, 2026Offer documentSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportAug 18, 2026Material contractSEC
424B3 · ProspectusAug 17, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveAug 17, 2026Other filingsSEC
8-K · Current reportAug 12, 2026Management or board changeSEC
4 · Change in ownershipAug 12, 2026Insider tradeSEC
8-K · Current reportAug 11, 2026Management or board changeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
4 · Change in ownershipAug 11, 2026Insider tradeSEC
10-Q · Quarterly reportAug 7, 2026Quarterly reportSEC
S-8 · Registration statement for employee plansAug 7, 2026Offer documentSEC
S-3 · Registration statementAug 7, 2026Offer documentSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
4 · Change in ownershipAug 7, 2026Insider tradeSEC
8-K · Current reportAug 6, 2026ResultsSEC
EFFECT · Notice that a registration is effectiveJul 28, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeJul 27, 2026Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJul 20, 2026Big-stake noticeSEC
S-3 · Registration statementJul 17, 2026Offer documentSEC
SCHEDULE 13G · Big-stake noticeJul 17, 2026Big-stake noticeSEC
4 · Change in ownershipJul 14, 2026Insider tradeSEC
8-K · Current reportJul 13, 2026Material contractSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
4 · Change in ownershipJul 7, 2026Insider tradeSEC
8-K · Current reportJul 6, 2026Material contractSEC
4 · Change in ownershipJun 30, 2026Insider tradeSEC
8-K · Current reportJun 23, 2026Meeting outcomeSEC
4 · Change in ownershipJun 16, 2026Insider tradeSEC
4 · Change in ownershipJun 2, 2026Insider tradeSEC
4 · Change in ownershipMay 19, 2026Insider tradeSEC
8-K · Current reportMay 15, 2026Management or board changeSEC
DEFA14A · Additional proxy materialMay 13, 2026Meeting noticeSEC
10-Q · Quarterly reportMay 11, 2026Quarterly reportSEC
8-K · Current reportMay 11, 2026ResultsSEC
4 · Change in ownershipMay 5, 2026Insider tradeSEC
ARS · Annual report to shareholdersApr 30, 2026Annual reportSEC
DEF 14A · Proxy statementApr 30, 2026Meeting noticeSEC
4 · Change in ownershipApr 28, 2026Insider tradeSEC
4 · Change in ownershipApr 28, 2026Insider tradeSEC
4 · Change in ownershipApr 28, 2026Insider tradeSEC
4 · Change in ownershipApr 28, 2026Insider tradeSEC
4 · Change in ownershipApr 28, 2026Insider tradeSEC
4 · Change in ownershipApr 28, 2026Insider tradeSEC
4 · Change in ownershipApr 28, 2026Insider tradeSEC
4 · Change in ownershipApr 28, 2026Insider tradeSEC
4 · Change in ownershipApr 21, 2026Insider tradeSEC
PRE 14A · Preliminary proxy statementApr 20, 2026Meeting noticeSEC
4 · Change in ownershipApr 13, 2026Insider tradeSEC
4 · Change in ownershipApr 6, 2026Insider tradeSEC
4 · Change in ownershipApr 2, 2026Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMar 26, 2026Big-stake noticeSEC
8-K · Current reportMar 26, 2026Current reportSEC
4 · Change in ownershipMar 24, 2026Insider tradeSEC
10-K · Annual reportMar 16, 2026Annual reportSEC
8-K · Current reportMar 16, 2026ResultsSEC
4 · Change in ownershipMar 9, 2026Insider tradeSEC
4 · Change in ownershipFeb 24, 2026Insider tradeSEC
4 · Change in ownershipFeb 9, 2026Insider tradeSEC
4 · Change in ownershipJan 26, 2026Insider tradeSEC
SCHEDULE 13D · Big-stake noticeJan 23, 2026Big-stake noticeSEC
3 · Initial statement of ownershipJan 16, 2026Insider tradeSEC
8-K · Current reportJan 16, 2026Acquisition or disposalSEC
8-K · Current reportJan 14, 2026Management or board changeSEC
4 · Change in ownershipJan 12, 2026Insider tradeSEC
8-K · Current reportJan 8, 2026Material contractSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
4 · Change in ownershipJan 5, 2026Insider tradeSEC
S-3ASR · Registration statementDec 29, 2025Offer documentSEC
4 · Change in ownershipDec 29, 2025Insider tradeSEC
4 · Change in ownershipDec 15, 2025Insider tradeSEC
4 · Change in ownershipDec 1, 2025Insider tradeSEC
4 · Change in ownershipNov 17, 2025Insider tradeSEC
10-Q · Quarterly reportNov 10, 2025Quarterly reportSEC
8-K · Current reportNov 10, 2025ResultsSEC
4 · Change in ownershipNov 5, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 30, 2025Big-stake noticeSEC
4 · Change in ownershipOct 21, 2025Insider tradeSEC
8-K · Current reportOct 9, 2025Material contractSEC
4 · Change in ownershipOct 6, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
4 · Change in ownershipOct 3, 2025Insider tradeSEC
8-K · Current reportSep 23, 2025Current reportSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
4 · Change in ownershipSep 9, 2025Insider tradeSEC
144 · Notice of proposed saleAug 29, 2025Other filingsSEC
4 · Change in ownershipAug 26, 2025Insider tradeSEC
S-8 · Registration statement for employee plansAug 11, 2025Offer documentSEC
10-Q · Quarterly reportAug 11, 2025Quarterly reportSEC
4 · Change in ownershipAug 11, 2025Insider tradeSEC
8-K · Current reportAug 11, 2025ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 29, 2025Big-stake noticeSEC
4 · Change in ownershipJul 28, 2025Insider tradeSEC
SCHEDULE 13G/A · Big-stake notice, amendedJul 16, 2025Big-stake noticeSEC
4 · Change in ownershipJul 15, 2025Insider tradeSEC
4 · Change in ownershipJul 15, 2025Insider tradeSEC
4 · Change in ownershipJul 3, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
4 · Change in ownershipJun 30, 2025Insider tradeSEC
8-K · Current reportJun 20, 2025Meeting outcomeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 20, 2025Insider tradeSEC
4 · Change in ownershipJun 17, 2025Insider tradeSEC
DEFR14AJun 6, 2025Meeting noticeSEC
8-K · Current reportJun 4, 2025Material contractSEC
4 · Change in ownershipJun 3, 2025Insider tradeSEC
EFFECT · Notice that a registration is effectiveJun 2, 2025Other filingsSEC
CORRESP · Letter to the SECMay 28, 2025Other filingsSEC
4 · Change in ownershipMay 20, 2025Insider tradeSEC
UPLOAD · Letter from the SECMay 15, 2025Other filingsSEC
S-3 · Registration statementMay 12, 2025Offer documentSEC
10-Q · Quarterly reportMay 12, 2025Quarterly reportSEC
8-K · Current reportMay 12, 2025ResultsSEC
4 · Change in ownershipMay 6, 2025Insider tradeSEC
DEFR14AMay 5, 2025Meeting noticeSEC
4 · Change in ownershipMay 5, 2025Insider tradeSEC
4 · Change in ownershipMay 5, 2025Insider tradeSEC
ARS · Annual report to shareholdersApr 30, 2025Annual reportSEC
DEF 14A · Proxy statementApr 30, 2025Meeting noticeSEC
4 · Change in ownershipApr 22, 2025Insider tradeSEC
PRE 14A · Preliminary proxy statementApr 18, 2025Meeting noticeSEC
4 · Change in ownershipApr 10, 2025Insider tradeSEC
4 · Change in ownershipApr 8, 2025Insider tradeSEC
4 · Change in ownershipApr 3, 2025Insider tradeSEC
4 · Change in ownershipApr 2, 2025Insider tradeSEC
4 · Change in ownershipMar 27, 2025Insider tradeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
4 · Change in ownershipMar 24, 2025Insider tradeSEC
10-K · Annual reportMar 17, 2025Annual reportSEC
4 · Change in ownershipMar 11, 2025Insider tradeSEC
4 · Change in ownershipMar 11, 2025Insider tradeSEC
8-K · Current reportMar 11, 2025ResultsSEC
4 · Change in ownershipMar 5, 2025Insider tradeSEC
8-K · Current reportFeb 26, 2025Material contractSEC
4 · Change in ownershipFeb 25, 2025Insider tradeSEC
4 · Change in ownershipFeb 18, 2025Insider tradeSEC
4 · Change in ownershipFeb 11, 2025Insider tradeSEC
8-K · Current reportFeb 10, 2025Current reportSEC
4 · Change in ownershipFeb 4, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 28, 2025Insider tradeSEC
4 · Change in ownershipJan 13, 2025Insider tradeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
4 · Change in ownershipJan 2, 2025Insider tradeSEC
4 · Change in ownershipDec 30, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
8-K · Current reportDec 5, 2024Current reportSEC
4 · Change in ownershipDec 3, 2024Insider tradeSEC
8-K · Current reportNov 27, 2024Material contractSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
4 · Change in ownershipNov 18, 2024Insider tradeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
SC 13G/A · Big-stake notice, amendedNov 14, 2024Big-stake noticeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
8-K · Current reportNov 12, 2024ResultsSEC
8-K/A · Current report, amendedNov 8, 2024Management or board changeSEC
SC 13G · Big-stake noticeNov 8, 2024Big-stake noticeSEC
8-K · Current reportNov 5, 2024Management or board changeSEC
4 · Change in ownershipNov 4, 2024Insider tradeSEC
SC 13G · Big-stake noticeOct 22, 2024Big-stake noticeSEC
4 · Change in ownershipOct 21, 2024Insider tradeSEC
4 · Change in ownershipOct 7, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipOct 3, 2024Insider tradeSEC
4 · Change in ownershipSep 24, 2024Insider tradeSEC
4 · Change in ownershipSep 9, 2024Insider tradeSEC
4 · Change in ownershipAug 27, 2024Insider tradeSEC
4 · Change in ownershipAug 12, 2024Insider tradeSEC
8-K · Current reportAug 8, 2024ResultsSEC
424B5 · ProspectusAug 8, 2024Offer documentSEC
3 · Initial statement of ownershipAug 8, 2024Insider tradeSEC
4 · Change in ownershipAug 8, 2024Insider tradeSEC
10-Q · Quarterly reportAug 8, 2024Quarterly reportSEC
8-K · Current reportAug 2, 2024Current reportSEC
4 · Change in ownershipJul 29, 2024Insider tradeSEC
4 · Change in ownershipJul 15, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
4 · Change in ownershipJul 1, 2024Insider tradeSEC
S-8 · Registration statement for employee plansJun 25, 2024Offer documentSEC
3 · Initial statement of ownershipJun 20, 2024Insider tradeSEC
4 · Change in ownershipJun 18, 2024Insider tradeSEC

This page holds 200 of 1,005 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Agenus Inc.’s releases · as of Nov 3, 2026

Common shares
45,246,510
Fully diluted
45,246,510

Fully diluted

LineSharesAs of
Common shares45,246,510Nov 3, 2026

Share count over time

CountShares
Nov 3, 202645,246,510

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Ra Capital Management, L.P.4.12M9.1%US$40.9MSep 30, 2026
Vanguard3.36M7.4%US$33.4MSep 30, 2026
BlackRock2.94M6.5%US$29.2MSep 30, 2026
Eventide Asset Management, LLC2.45M5.4%US$24.3MSep 30, 2026
Siren, L.L.C.2.42M5.3%US$24MSep 30, 2026
Commodore Capital LP1.99M4.4%US$19.7MSep 30, 2026
Geode Capital1.01M2.2%US$10MSep 30, 2026
Goldman Sachs825K1.8%US$8.19MSep 30, 2026
Marshall Wace, LLP786K1.7%US$7.81MSep 30, 2026
State Street756K1.7%US$7.51MSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
TCG Crossover Management, LLC604K1.3%US$6MSep 30, 2026
Globeflex Capital L P419K0.93%US$4.16MSep 30, 2026
Morgan Stanley381K0.84%US$3.78MSep 30, 2026
Susquehanna379K0.84%US$3.76MSep 30, 2026
Northern Trust297K0.66%US$2.95MSep 30, 2026
Renaissance Technologies281K0.62%US$2.79MSep 30, 2026
D. E. Shaw & Co., Inc.240K0.53%US$2.38MSep 30, 2026
UBS211K0.47%US$2.1MSep 30, 2026
XTX Topco Ltd179K0.40%US$1.78MSep 30, 2026
Connor, Clark & Lunn Investment Management Ltd.158K0.35%US$1.57MSep 30, 2026
Two Sigma157K0.35%US$1.56MSep 30, 2026
First Trust153K0.34%US$1.51MSep 30, 2026
AQR Capital Management LLC152K0.34%US$1.51MSep 30, 2026
Point72 Asset Management, L.P.151K0.33%US$1.5MSep 30, 2026
Wellington144K0.32%US$1.43MSep 30, 2026
Prudential Financial Inc128K0.28%US$1.27MSep 30, 2026
BNY124K0.27%US$1.23MSep 30, 2026
Citadel124K0.27%US$1.23MSep 30, 2026
Schwab111K0.25%US$1.11MSep 30, 2026
Panagora Asset Management Inc99,2460.22%US$986KSep 30, 2026
Nuveen79,8500.18%US$793KSep 30, 2026
Jane Street64,3870.14%US$639KSep 30, 2026
Man Group plc63,2540.14%US$628KSep 30, 2026
HighTower Advisors, LLC57,7910.13%US$574KSep 30, 2026
T. Rowe Price57,6560.13%US$573KSep 30, 2026
Rhumbline Advisers50,6310.11%US$503KSep 30, 2026
Strs Ohio46,5000.10%US$462KSep 30, 2026
JPMorgan45,4110.10%US$449KSep 30, 2026
Captrust Financial Advisors38,8700.09%US$386KSep 30, 2026
Bank of America35,5970.08%US$353KSep 30, 2026
Invesco35,5580.08%US$353KSep 30, 2026
Creative Planning34,6520.08%US$344KSep 30, 2026
DWS33,8160.07%US$336KSep 30, 2026
Claro Advisors Inc.26,1960.06%US$260KSep 30, 2026
LPL Financial LLC24,1770.05%US$240KSep 30, 2026
Osaic Holdings, Inc.23,4500.05%US$232KSep 30, 2026
State of Wyoming22,7010.05%US$225KSep 30, 2026
Squarepoint Ops LLC22,4250.05%US$223KSep 30, 2026
MetLife Investment Management, LLC22,2710.05%US$221KSep 30, 2026
Group One Trading LLC20,4560.05%US$203KSep 30, 2026

This page holds 50 of 120 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund1.16M2.6%US$3.55MJun 30, 2026
iShares Russell 2000 ETF904K2.0%US$2.77MJun 30, 2026
Vanguard Strategic Equity Fund512K1.1%US$1.57MJun 30, 2026
Vanguard Extended Market Index Fund485K1.1%US$1.48MJun 30, 2026
Fidelity Small Cap Index Fund436K0.96%US$3.27MJul 31, 2026
Vanguard Explorer Fund291K0.64%US$2.18MJul 31, 2026
iShares Russell 2000 Value ETF258K0.57%US$791KJun 30, 2026
iShares Russell 2000 Growth ETF257K0.57%US$786KJun 30, 2026
Vanguard Strategic Small-Cap Equity Fund205K0.45%US$628KJun 30, 2026
Fidelity Extended Market Index Fund164K0.36%US$574KMay 31, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
iShares Micro-Cap ETF134K0.30%US$410KJun 30, 2026
Small Company Growth Portfolio115K0.25%US$351KJun 30, 2026
Schwab Small-Cap Index Fund96,3100.21%US$722KJul 31, 2026
Siit Small Cap II Fund84,7000.19%US$296KMay 31, 2026
Master Small Cap Index Series74,4800.16%US$228KJun 30, 2026
Fidelity Total Market Index Fund60,5520.13%US$212KMay 31, 2026
Fidelity Series Total Market Index Fund50,6430.11%US$177KMay 31, 2026
Fidelity Small Cap Value Index Fund47,6060.11%US$146KJun 30, 2026
Acuitas US Microcap Fund45,5030.10%US$139KJun 30, 2026
EQ/2000 Managed Volatility Portfolio40,4070.09%US$124KJun 30, 2026
PGIM Quant Solutions Small-Cap Value Fund39,5000.09%US$296KJul 31, 2026
Goldman Sachs Absolute Return Tracker Fund39,2180.09%US$120KJun 30, 2026
Vanguard Market Neutral Fund33,5740.07%US$103KJun 30, 2026
LVIP State Street Small-Cap Index Fund31,1000.07%US$95,166Jun 30, 2026
T. Rowe Price Extended Equity Market Index Fund24,5000.05%US$74,970Jun 30, 2026
Fidelity ZERO Total Market Index Fund23,0810.05%US$173KJul 31, 2026
Fidelity Nasdaq Composite Index Fund22,6040.05%US$79,114May 31, 2026
Small Cap Index Fund21,1380.05%US$64,682Jun 30, 2026
Vanguard Balanced Index Fund20,3810.05%US$62,366Jun 30, 2026
Global X Russell 2000 ETF19,0520.04%US$143KJul 31, 2026
Fidelity ZERO Extended Market Index Fund15,2590.03%US$114KJul 31, 2026
Schwab Total Stock Market Index Fund15,0000.03%US$113KJul 31, 2026
Small-Cap Index Portfolio11,0170.02%US$33,712Jun 30, 2026
Vanguard Institutional Total Stock Market Index Fund10,8850.02%US$33,308Jun 30, 2026
1290 VT Micro Cap Portfolio9,0370.02%US$27,653Jun 30, 2026
ATM Small Cap Managed Volatility Portfolio8,3880.02%US$25,667Jun 30, 2026
NVIT Small Cap Index Fund8,2580.02%US$25,269Jun 30, 2026
Fidelity Flex Small Cap Index Fund6,7140.01%US$50,355Jul 31, 2026
EQ/Small Company Index Portfolio6,1900.01%US$18,941Jun 30, 2026
EQ/AB Small Cap Growth Portfolio6,1900.01%US$18,941Jun 30, 2026
DWS Small Cap Index VIP6,1770.01%US$18,902Jun 30, 2026
T. Rowe Price Small-Cap Index Fund6,0780.01%US$18,599Jun 30, 2026
Fidelity Small Cap Growth Index Fund5,6050.01%US$17,151Jun 30, 2026
BlackRock Small Cap Index V.I. Fund5,1940.01%US$15,894Jun 30, 2026
1290 VT Small Cap Value Portfolio4,8680.01%US$14,896Jun 30, 2026
SA Small Cap Index Portfolio4,6660.01%US$34,995Jul 31, 2026
Victory Extended Market Index Fund4,329<0.01%US$32,468Jul 31, 2026
CVT Russell 2000 Small Cap Index Portfolio3,616<0.01%US$11,065Jun 30, 2026
Nationwide Small Cap Index Fund3,415<0.01%US$25,613Jul 31, 2026
Venerable Small Cap Index Fund3,181<0.01%US$9,734Jun 30, 2026

This page holds 50 of 71 holders. Open Shareholders

Big stakes

StakeStakeSharesDateFiling
TCG Crossover GP III, LLC9.99%4.95MSep 30, 2026Schedule 13G
Raymond Debbane9.99%4.53MJul 13, 2026Schedule 13G
Ra Capital Management, L.P.9.90%4.34MJul 13, 2026Schedule 13G
BlackRock, Inc.6.00%2.51MJun 30, 2026Schedule 13G
ZYNEXT VENTURES USA LLC5.90%2.13MJan 15, 2026Schedule 13D
Eventide Asset Management, LLC5.40%2.45MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Noubar Afeyan
Other companies: Generate Biomedicines, Inc. (Chair of the Board · Since at least Feb 26, 2026); Foghorn Therapeutics Inc. (Director · Since at least Jan 13, 2026); Moderna, Inc. (Director · Since at least Dec 7, 2018); BG Medicine Inc (Director · Since at least Feb 3, 2011); Omega Therapeutics Inc (Director · Jul 29, 2021 – Jun 7, 2023 · Past); Kaleido Biosciences, Inc. (Director · Feb 27, 2019 – Mar 4, 2019 · Past); Rubius Therapeutics Inc (Director · Jul 17, 2018 – May 12, 2022 · Past); Evelo Biosciences, Inc. (Director · May 8, 2018 – Jun 12, 2019 · Past); Cartesian Therapeutics, Inc. (Director · Jun 21, 2016 – Jun 21, 2016 · Past); Seres Therapeutics, Inc. (Director · Jun 25, 2015 – Jun 18, 2019 · Past); Eleven Biotherapeutics Inc (Director · Feb 5, 2014 – Mar 20, 2014 · Past); BIND Therapeutics Inc (Director · Sep 19, 2013 – Sep 25, 2013 · Past); Color Kinetics Inc (Director · Jan 3, 2006 – Aug 24, 2007 · Past)
Director · Jan 13, 2005 – Jun 7, 2007 · Past
Shalini Sharp
Other companies: Iambic Therapeutics, Inc. (Board Member · Since at least Nov 5, 2026); BeOne Medicines Ltd. Class A (Director · Since at least Jun 11, 2026); Septerna, Inc. (Director · Since at least Oct 24, 2024); Organon & Co. (Director · Since at least May 14, 2021); Neurocrine Biosciences, Inc. (Director · Since at least Feb 1, 2020); Nuvation Bio Inc. (Director · Jun 30, 2020 – Feb 10, 2021 · Past); Precision BioSciences, Inc. (Director · Mar 27, 2019 – May 10, 2021 · Past); Sutro Biopharma, Inc. (Director · Nov 8, 2018 – Jun 6, 2022 · Past); Ultragenyx Pharmaceutical Inc. (EVP, Finance · Jan 30, 2014 – Oct 14, 2020 · Past)
Director · Oct 1, 2006 – Mar 2, 2018 · Past
Thomas Harrison
Other companies: Acurx Pharmaceuticals, Inc. (Director · Since at least Jun 24, 2021); Advanced Flower Capital Inc. (Director · Since at least Mar 18, 2021); Zynerba Pharmaceuticals Inc (Director · Aug 4, 2015 – Jun 6, 2018 · Past); Fifth Street Asset Management Inc (Director · Oct 29, 2014 – Dec 8, 2017 · Past); PLx Pharma Inc (Director · Mar 12, 2014 – Jan 17, 2017 · Past); rVue Holdings Inc (Director · Sep 19, 2013 – Dec 3, 2013 · Past); Epocrates Inc (Director · Feb 1, 2011 – Mar 12, 2013 · Past); Omnicom Group Inc. (Chrmn/CEO Divers. Agency Serv. · May 4, 2006 – Mar 31, 2010 · Past); Morgans Hotel Group Company (Director · Feb 13, 2006 – May 17, 2012 · Past)
Director · Since at least Aug 7, 2024
Paul N Clark
Other companies: Keysight Technologies Inc. (Director · Oct 6, 2014 – Mar 19, 2021 · Past); Talecris Biotherapeutics Holdings Corp (Director · Sep 30, 2009 – Jun 1, 2011 · Past); Amylin Pharmaceuticals LLC (Director · Jun 9, 2009 – Apr 9, 2012 · Past); Agilent Technologies, Inc. (Director · May 17, 2006 – Mar 18, 2021 · Past); Icos Corp (Chairman, CEO & President, Director · Jan 24, 2006 – Jan 29, 2007 · Past)
Director · Aug 27, 2020 – Apr 1, 2021 · Past
John N. Hatsopoulos
Other companies: Tecogen Inc. (Lead Director · Since at least Oct 1, 2013); EuroSite Power Inc (Director · Jul 25, 2012 – May 12, 2016 · Past); American DG Energy Inc (Co-Chief Executive Officer, Director · Mar 19, 2008 – May 23, 2017 · Past); American Caresource Holdings Inc (Director · Dec 31, 2007 – Jul 20, 2010 · Past)
Director · Jun 7, 2007 – Dec 8, 2011 · Past
Shahzad Malik
Other companies: Acutus Medical Inc. (Director · Aug 5, 2020 – Jun 17, 2021 · Past); Axonics Modulation Technologies Inc (Director · Oct 30, 2018 – Dec 6, 2018 · Past); Histogen Inc (Director · Jun 23, 2016 – Jun 23, 2016 · Past); Aravive Inc (Director · Jun 29, 2015 – Sep 12, 2019 · Past)
Director · Jun 15, 2016 – Jun 15, 2016 · Past
Charles Evan Ballantyne
Other companies: Gain Therapeutics, Inc. (Chief Financial Officer · Apr 10, 2023 – Apr 10, 2023 · Past); Theriva Biologics, Inc. (Chief Financial Officer · Feb 6, 2012 – Jan 8, 2015 · Past); Clinical Data Inc (EVP, CFO · Jun 14, 2007 – Apr 12, 2011 · Past)
CFO · Jun 17, 2015 – Jun 14, 2016 · Past
Garo H. Armen
Other companies: Protagenic Therapeutics, Inc. (EXEC. CHAIR & PRINCIPAL OFF, Director · Since at least Feb 12, 2016); MiNK Therapeutics, Inc. (Director · Oct 13, 2021 – May 5, 2023 · Past); Color Kinetics Inc (Director · May 24, 2006 – Aug 24, 2007 · Past)
Chairman and Chief Executive Officer · Since at least Feb 22, 2006
Hyam Levitsky
Other companies: Century Therapeutics, Inc. (President of R&D · Jun 17, 2021 – Mar 7, 2024 · Past); Replimune Group, Inc. (Director · Jul 19, 2018 – Apr 1, 2024 · Past); Juno Therapeutics Inc (EVP, Research & CSO · May 27, 2015 – Feb 7, 2017 · Past)
Director · Sep 13, 2006 – Aug 28, 2011 · Past
Mark Kessel
Other companies: VivoSim Labs, Inc. (Director · Aug 17, 2016 – Sep 5, 2019 · Past); Dynavax Technologies Corporation (Director · Dec 30, 2009 – Oct 16, 2012 · Past); Oncotelic Therapeutics Inc (Director · Oct 22, 2008 – Oct 31, 2011 · Past)
Director · Jan 13, 2006 – Oct 2, 2006 · Past
All 40 people
PersonSeat
Timothy R. Wright
Other companies: Protagenic Therapeutics, Inc. (Director · Mar 25, 2024 – Mar 25, 2024 · Past); MiMedx Group, Inc (Chief Executive Officer, Director · May 13, 2019 – Jun 9, 2022 · Past); Covidien plc (Senior Vice President · Jun 29, 2007 – Dec 1, 2010 · Past)
Lead Director · Since at least Dec 7, 2006
Brian Corvese
Other companies: MiNK Therapeutics, Inc. (Director · Since at least Oct 13, 2021); Protagenic Therapeutics, Inc. (Director · Mar 25, 2024 – Mar 25, 2024 · Past)
Director · Since at least Dec 17, 2020
Christine M Klaskin
Other companies: MiNK Therapeutics, Inc. (Treasurer · Oct 13, 2021 – Oct 13, 2021 · Past); American DG Energy Inc (Director · Jan 18, 2012 – May 23, 2017 · Past)
PFO & PAO · Since at least Feb 12, 2008
Jennifer Buell
Other companies: MiNK Therapeutics, Inc. (President and CEO · Since at least Oct 13, 2021); Protagenic Therapeutics, Inc. (Director · Jul 18, 2020 – Mar 25, 2024 · Past)
President and CEO of MiNK Therapeutics and Chairman, Executive Council at Agenus · Since at least Jun 29, 2017
Kerry Wentworth
Other companies: Nuvation Bio Inc. (Chief Regulatory Officer · Since at least May 23, 2022); Flexion Therapeutics Inc (Chief Regulatory Officer · Dec 21, 2017 – Nov 19, 2021 · Past)
VP, Clinical, Reg & Qual · Jul 20, 2006 – Feb 26, 2014 · Past
Renu Gupta
Other companies: Corbus Pharmaceuticals Holdings, Inc. (Director · Nov 24, 2014 – May 25, 2017 · Past); Insmed Incorporated (Executive Vice President & CMO · Dec 1, 2010 – Jan 31, 2014 · Past)
Sr. VP Development · Feb 24, 2006 – Jul 20, 2006 · Past
Austin Charette
Other companies: MiNK Therapeutics, Inc. (Principal Accounting Officer · Since at least Mar 13, 2026)
Principal Accounting Officer · Since at least Jan 8, 2026
Bruce Leicher
Other companies: Momenta Pharmaceuticals Inc (SVP & General Counsel · Jul 24, 2008 – Aug 21, 2018 · Past)
VP, General Counsel · Sep 15, 2006 – Dec 15, 2006 · Past
Christian Cortis
Other companies: Tectonic Therapeutic, Inc. (Chief Operating Officer · Jun 20, 2024 – Jun 20, 2024 · Past)
Chief Strategy Officer · Jun 19, 2019 – Jul 23, 2019 · Past
Frank V Atlee III
Other companies: Monsanto (Director · Jan 27, 2006 – Dec 20, 2010 · Past)
Director · Jan 13, 2006 – Jun 7, 2007 · Past
Susan Hirsch
Other companies: Tecogen Inc. (Director · Since at least Sep 22, 2023)
Managing Director at Nuveen · Since at least Oct 8, 2020
Ulf Wiinberg
Other companies: MiNK Therapeutics, Inc. (Director · Since at least Oct 13, 2021)
Director · May 17, 2016 – Oct 1, 2024 · Past
Adam KraussChief Legal Officer · Dec 17, 2020 – Jun 15, 2021 · Past
Alex DuncanChief Technology Officer · Jun 19, 2019 – Jul 23, 2019 · Past
Allison M Jeynes-EllisDirector · Nov 7, 2018 – Feb 5, 2024 · Past
Craig WinterChief Information Officer · Since at least Nov 4, 2026
Gamil De ChadarevianDirector · Feb 28, 2006 – Feb 28, 2006 · Past
José IglesiasChief Medical Affairs Officer · Since at least Nov 18, 2025
Marco Tullio MarcucciDirector · Since at least Aug 5, 2026
Ozer BaysalChief Commercial Officer · Apr 26, 2016 – Jun 20, 2018 · Past
Pramod SrivastavaDirector · Feb 23, 2006 – Jun 7, 2007 · Past
Robin TaylorChief Commercial Officer · Since at least Nov 2, 2026
Roman ChiczSr. VP, Research & Development · Feb 24, 2006 – May 18, 2007 · Past
Steven J O'DayChief Medical Officer · Since at least Feb 10, 2021
Steven O’DayChief Medical Officer · Since at least Nov 2, 2026
Tom DechaeneDirector · Jun 7, 2007 – Jan 4, 2016 · Past
Tom HarrisonDirector · Since at least Oct 2, 2026
Tracy Mazza ClementeChief People Officer · Since at least Nov 4, 2026
Wadih JordanDirector · Apr 1, 2010 – Oct 3, 2022 · Past
Zack ArmenVP, Corporate Development & Investor Relations · Since at least Nov 2, 2026

Open People

Log in to ask 6ix AI your own questions about Agenus Inc.